Alexion has said it can ramp up production if the drug works in trials but what it has not mentioned is its cost: Ultomiris is hugely expensive when used in rare diseases, costing several thousand ...

AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

This will allow quick identification of new safety information ... Read before using this medicine. Ultomiris contains the active ingredient ravulizumab rch. For more information, see Section ...